BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

Show other versions (1)

Bibliographic Details
Main Authors:	Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppa, S
Format:	Conference item
Published:	2008

Similar Items

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
by: Nyman, H, et al.
Published: (2009)

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
by: Nyman, H, et al.
Published: (2009)

The significance of FOXP1 in diffuse large B-cell lymphoma
by: Gascoyne, D, et al.
Published: (2016)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
by: Marta Rodríguez, et al.
Published: (2022-08-01)

MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
by: Borovecki, A, et al.
Published: (2007)

Strong expression of FOXP1 predicts for poor prognosis within the non-germinal centre subgroup of diffuse large B cell lymphoma
by: Barrans, S, et al.
Published: (2005)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
by: Camilleri, E, et al.
Published: (2012)

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.
by: Minna Taskinen, et al.
Published: (2014-01-01)

Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy
by: Nai-Wen Kang, et al.
Published: (2017-12-01)

Is FOXP3 expressed in cutaneous T-cell lymphomas?
by: Banham, A, et al.
Published: (2008)

The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma
by: Kathrine T. Isaksen, et al.
Published: (2021-02-01)

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
by: Kristiina Karihtala, et al.
Published: (2022-10-01)

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
by: Alexandra Valera, et al.
Published: (2013-10-01)

Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas
by: Rubini Corrado, et al.
Published: (2011-10-01)

Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas
by: Matias Autio, et al.
Published: (2024-12-01)

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
by: Matias Autio, et al.
Published: (2020-02-01)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
by: Christine Schmitz, et al.
Published: (2020-11-01)

FOXP3 expression in B and T cell lymphomas.
by: Roncador, G, et al.
Published: (2005)

The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma
by: Man Sun, et al.
Published: (2024-12-01)

Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
by: Amen, F, et al.
Published: (2007)

P1189: ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY
by: Ronakrit Thanhakun, et al.
Published: (2023-08-01)

Clinical Characteristics and Risk of Relapse for Patients with Stage I–II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy
by: S. Mercadal, et al.
Published: (2013-11-01)

Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy
by: S. Mercadal, et al.
Published: (2013-01-01)

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma
by: Alexandar Tzankov, et al.
Published: (2008-02-01)

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
by: Barrans, S, et al.
Published: (2004)

Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
by: Teerachat Punnachet, et al.
Published: (2024-10-01)

Prediction of immunochemotherapy response for diffuse large B‐cell lymphoma using artificial intelligence digital pathology
by: Jeong Hoon Lee, et al.
Published: (2024-05-01)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
by: Kathrine T. Isaksen, et al.
Published: (2023-03-01)

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
by: Leo Meriranta, et al.
Published: (2017-05-01)

Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
by: Barrans, S, et al.
Published: (2007)

The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.
by: Brown, P, et al.
Published: (2005)

Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
by: Banham, A, et al.
Published: (2005)

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
by: Sari Riihijärvi, et al.
Published: (2015-02-01)

Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation.
by: Haralambieva, E, et al.
Published: (2006)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
by: Jéssica Santos Cunha, et al.
Published: (2021-03-01)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
by: Sang Eun Yoon, et al.
Published: (2023-11-01)

Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
by: Maja Ludvigsen, et al.
Published: (2023-10-01)

Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement
by: Sharon L. Barrans, et al.
Published: (2007-06-01)

BCL2 overexpression in diffuse large B-cell Lymphoma
by: Hajar Masrour, et al.
Published: (2023-01-01)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
by: Wong, K, et al.
Published: (2014)